Day One Biopharmaceuticals

Inactive

DAWN (NasdaqGS)

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharma focused on developing medicines for pediatric and adult diseases in the United States. Its lead candidate, tovorafenib, is in Phase II for pediatric relapsed/refractory low-grade glioma. The company is also advancing DAY301, a PTK7-targeted ADC, and Emi-Le, an anti-B7-H4 ADC from Mersana’s platform in Phase 1 trials for several solid tumors. Founded in 2018 and based in Brisbane, California.